Glycemic and Lipid Outcomes Associated with Bitter Melon Blood-Sugar-Modulating Protein and Metformin Use: A Translational Preclinical and Retrospective Study.

In db/db mice, BMP combined with metformin produced greater glucose-lowering efficacy than metformin alone.

• The combination of BMP and metformin reduced fasting blood glucose by approximately 300 mg/dL compared to approximately 200 mg/dL for metformin alone (p < 0.05).
• BMP alone also significantly reduced fasting blood glucose and HbA1c in db/db mice.
• The db/db mouse model was used as a preclinical translational model for type 2 diabetes.

Skeletal muscle transcriptomic analysis in db/db mice identified 27 shared pathways regulated by BMP and metformin combination treatment.

• The 27 coordinated pathways were involved in glucose and lipid metabolism.
• Transcriptomic analysis revealed 'coordinated regulation' of these pathways.
• This pathway-level analysis was used to characterize the mechanistic basis for the observed metabolic effects.

BMP was characterized by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).

• This characterization was part of the mechanistic evaluation component of the translational study design.
• BMP is described as 'a major protein component of bitter melon.'
• The protein characterization was conducted alongside the animal and clinical arms of the study.

In the clinical cohort, BMP supplementation was associated with significant reductions in HbA1c among metformin users but not among non-users.

• HbA1c decreased by -0.23% (p = 0.0028) among metformin users receiving daily BMP supplementation.
• No significant changes in HbA1c were observed in non-metformin users.
• The clinical arm was a retrospective, self-controlled observational cohort of 119 individuals with prediabetes or diabetes followed over 3 months.
• The study authors noted that 'these clinical findings reflect observational associations rather than causal effects' given the retrospective, self-controlled design and baseline clinical differences between groups.

BMP supplementation was associated with reductions in total cholesterol and LDL cholesterol among metformin users in the clinical cohort.

• Total cholesterol decreased by -7.5 mg/dL among metformin users.
• Low-density lipoprotein (LDL) cholesterol decreased by -6.1 mg/dL among metformin users.
• No significant lipid changes were reported in non-metformin users.
• Lipid profiles were among the outcomes evaluated over the 3-month observation period.

The greatest observed HbA1c reduction occurred in participants receiving 1000 mg/day of metformin concurrently with BMP supplementation.

• HbA1c reduction of -0.32% (p < 0.0001) was observed in participants on 1000 mg/day metformin.
• This was greater than the -0.23% reduction observed across all metformin users.
• Participants were stratified by metformin use and dosage to assess dose-dependent associations.

The study used a retrospective self-controlled design in the clinical arm, with participants serving as their own controls.

• The clinical cohort included 119 individuals with prediabetes or diabetes.
• Participants received daily BMP supplementation and were stratified by metformin use and dosage.
• The observation period was 3 months.
• Authors acknowledged 'baseline clinical differences between treatment groups' as a limitation affecting causal interpretation.

This study is described as the first to demonstrate complementary metabolic effects of BMP when combined with first-line antidiabetic therapy in animal models with a corresponding human observational association.

• The authors state this is 'the first to demonstrate that BMP, a major protein component of bitter melon, exhibits complementary metabolic effects when combined with first-line antidiabetic therapy in animal models.'
• The study is described as establishing 'an important foundation for nutritional protein research.'
• The translational design combined preclinical mechanistic data with a real-world observational cohort.